Evidence map›Paper›PMID 36817443›Full record

Trial reportFrontiers in immunology2023

Immunotherapy in cervical cancer: From the view of scientometric analysis and clinical trials.

Yang Xing, Feroza Yasinjan, Yajie Du, Huayue Geng, Ying Zhang, Minghua He, Rui Guo, Lei Yang, Jiayue Cui, Dongmei Mu and 2 more

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Yang XingCancer Center, The First Hospital of Jilin University, Changchun, China.
Feroza YasinjanCancer Center, The First Hospital of Jilin University, Changchun, China.
Yajie DuCancer Center, The First Hospital of Jilin University, Changchun, China.
Huayue GengCancer Center, The First Hospital of Jilin University, Changchun, China.
Ying ZhangCancer Center, The First Hospital of Jilin University, Changchun, China.
Minghua HeCollege of Computer Science and Technology, Jilin University, Changchun, China.
Rui GuoClinical Laboratory, The First Hospital of Jilin University, Changchun, China.
Lei YangCancer Center, The First Hospital of Jilin University, Changchun, China.
Jiayue CuiDepartment of Histology and Embryology, College of Basic Medical Sciences, Jilin University, Changchun, China.
Dongmei MuDivision of Clinical Research, The First Hospital of Jilin University, Changchun, China.
Ziling LiuCancer Center, The First Hospital of Jilin University, Changchun, China.
Hong WangCancer Center, The First Hospital of Jilin University, Changchun, China.
Jilin University · CNFirst Hospital of Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cervical cancer is the fourth most cancer and the fourth leading cause of cancer-related deaths in women worldwide. Current treatment for patients with advanced cervical cancer is limited. And in the urgent demand for novel effective therapies both as the first and the second line treatment for these patients, immunotherapy is developing fast and has made some achievements. Methods: This study incorporated 1,255 topic-related articles and reviews from 1999 to 2022 in the Web of Science Core Collection (WoSCC). The WoS platform, Citespace, and VOS viewer provided the annual distribution of publications and citations, the analysis of researching countries and institutions, references, keywords (co-occurrence analysis, burst analysis, and timeline view analysis), and researching authors, respectively. For clinical trials, 720 trials and 114 trials from ClinicalTrials.gov and ICTRP were retrieved, respectively. And 296 trials were finally incorporated into the analysis. Results: The scientometric analysis showed that the study of immunotherapies in cervical cancer developed fast in recent years. Most publications were from the United States, followed by China. Seven of the top 10 co-cited references belong to clinical trials, and five of them were published in recent five years. There are lots of clinical trials us specific treatment patterns, some of which have represented excellent effects. Conclusions: Both the scientometric analysis of the 1,255 publications and the analysis of clinical trials showed that the field of immunotherapies in cervical cancer developed so fast in recent years. It was found that a lot of clinical trials using various immunotherapies (mainly vaccine therapy, adoptive cell therapy, immune checkpoint blockade, and antibody-drug conjugate) for advanced cervical cancer are currently ongoing or have represented considerable effect. Centered in immunotherapies, immune checkpoint blockades have represented great efficacy and huge potential, especially combined with other therapies such as chemotherapy, targeted therapy, and other immunotherapies.

Indexed as

ImmunoconjugatesUterine Cervical NeoplasmsCell- and Tissue-Based TherapyChinaFemaleHumansImmunotherapyImmunoconjugatescervical cancerclinical trialsHPVimmunotherapyscientometric analysis

Identifiers

PMID36817443
PMCPMC9935705
OpenAlexW4319161932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.